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SIRT3-mediated inhibition of FOS through histone H3
deacetylation prevents cardiac fibrosis and inflammation
Xavier Palomer1, M. Silvia Román-Azcona1, Javier Pizarro-Delgado1, Ana Planavila2, Francesc Villarroya2, Brenda Valenzuela-Alcaraz3,
Fátima Crispi3, Álvaro Sepúlveda-Martínez3, Irene Miguel-Escalada4, Jorge Ferrer4,5, J. Francisco Nistal6, Raquel García7,
Mercy M. Davidson8, Emma Barroso1 and Manuel Vázquez-Carrera 1
Sirtuin 3 (SIRT3) is a deacetylase that modulates proteins that control metabolism and protects against oxidative stress. Modulation
of SIRT3 activity has been proposed as a promising therapeutic target for ameliorating metabolic diseases and associated cardiac
disturbances. In this study, we investigated the role of SIRT3 in inflammation and fibrosis in the heart using male mice with
constitutive and systemic deletion of SIRT3 and human cardiac AC16 cells. SIRT3 knockout mice showed cardiac fibrosis and
inflammation that was characterized by augmented transcriptional activity of AP-1. Consistent with this, SIRT3 overexpression in
human and neonatal rat cardiomyocytes partially prevented the inflammatory and profibrotic response induced by TNF-α. Notably,
these effects were associated with a decrease in the mRNA and protein levels of FOS and the DNA-binding activity of AP-1. Finally,
we demonstrated that SIRT3 inhibits FOS transcription through specific histone H3 lysine K27 deacetylation at its promoter. These
findings highlight an important function of SIRT3 in mediating the often intricate profibrotic and proinflammatory responses of
cardiac cells through the modulation of the FOS/AP-1 pathway. Since fibrosis and inflammation are crucial in the progression of
cardiac hypertrophy, heart failure, and diabetic cardiomyopathy, our results point to SIRT3 as a potential target for treating these
diseases.
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INTRODUCTION
In response to diverse pathological stimuli, the heart may
secrete numerous proinflammatory mediators, such as inter-
leukin (IL)6, monocyte chemoattractant protein 1 (MCP1), and
tumor necrosis factor (TNF)-α, which are under the control of the
transcription factor nuclear factor-κB (NF-κB).1,2 These mediators
locally enhance inflammation through their pleiotropic auto-
crine effects, which are carried out via downstream activation of
NF-κB itself, activator protein-1 (AP-1) and nuclear factor of
activated T-cells (NFAT), all associated with cardiovascular
disease development and progression.2–4 For instance, TNF-α
overproduction is boosted in the cardiac tissue of hypertensive
rodents and human subjects with heart failure, which con-
tributes to remodeling and functional impairment of the heart
and accelerates the development of heart failure.5 Similarly,
continuous cardiac secretion of TNF-α after transplantation
favors cardiac allograft hypertrophy.6 In addition to cytokines
and chemokines, several other factors may enhance NF-κB
transcriptional activity, such as hyperglycemia, increased free
fatty acid levels or reactive oxygen species (ROS).1
Myocardial injury caused by inflammatory processes results in
left ventricular remodeling, characterized by myocyte hypertro-
phy, loss of functioning myocytes and interstitial fibrosis, which
eventually transitions to cardiac hypertrophy and heart failure.1,2
Tissue fibrosis is a distinct deleterious alteration that is observed in
several cardiac diseases. It occurs because of excess accumulation
of extracellular matrix proteins in cardiac tissue7 in a process that
is regulated by AP-1 and NF-κB, among others. AP-1 binds to
specific promoter elements in target genes to regulate mRNA
expression in response to inflammatory stimuli.8 In the heart, AP-1
induces the deposition of collagen and the synthesis of
endothelin-1, fibronectin, and transforming growth factor-β
(TGF-β).4,7,9 By these means, AP-1 brings about modifications to
the extracellular matrix and reduces cardiac contractility, inducing
fibrosis of the interstitial substance and cardiomyocyte hyper-
trophy, eventually leading to heart failure.4
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Several studies have revealed multiple important links between
the sirtuin family of proteins and inflammatory processes.
Transgenic mice with forced overexpression of SIRT1 that were
fed a Western-type diet show decreased inflammation due to
downmodulation of NF-κB activity.10 More recently, SIRT6 has
been shown to attenuate NF-κB-dependent gene expression via
histone H3 deacetylation at the chromatin.11 Sirtuins are NAD-
dependent protein deacetylases that are regarded as major
regulators of cellular functions. SIRT3 is ubiquitously expressed,
although it is particularly expressed in organs and tissues with a
high metabolic rate capacity, including the heart.12 Protein targets
of SIRT3 include mitochondrial enzymes that regulate energy
metabolism, through which SIRT3 indirectly controls the produc-
tion of ROS. Thus, SIRT3 has a protective effect against oxidative
stress-dependent disorders. Recent studies have demonstrated
that SIRT3 knockout mice display mitochondrial protein hyper-
acetylation13 and a significant reduction in ATP production in the
heart.14 It is worth mentioning that SIRT3 is overexpressed in
experimental models of cardiac hypertrophy, whereas SIRT3
overexpression partially blunts the cardiac hypertrophic response
by regulating antioxidant gene expression and the activity of the
mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) and AMP-activated protein kinase (AMPK)
pathways12,15,16 and by attenuating lipid accumulation in cardi-
omyocytes.17 Of note, SIRT3 reverses palmitate-induced inflam-
mation in cultured proximal tubular cells.18 In this study, we
investigated the promising anti-inflammatory role of SIRT3 in the
heart by examining the effects of this deacetylase on TNF-α-
induced inflammation and fibrosis in cardiac cells of human origin
and in SIRT3 knockout mice.
RESULTS
SIRT3 knockout mice display inflammation in the heart
No differences were found in body weight or cardiac hypertrophic
markers between SIRT3 knockout and wild-type mice (Fig. 1).
However, SIRT3 knockout mice showed an increase in myocardial
expression of intercellular adhesion molecule 1 (Icam1), Il6, Mcp1,
suppressor of cytokine signaling 3 (Socs3), and superoxide
dismutase 2 (Sod2) (Fig. 2a). This inflammatory profile did not
arise from systemic inflammation, as plasma IL6 and MCP1 levels
were not increased in knockout mice (Supplementary Fig. S1c) and
was not a consequence of increased macrophage infiltration in
the heart, as suggested by the absence of changes in the
expression of adhesion G protein-coupled receptor E1 (Adgre1)
and Cd68, which are widely recognized as macrophage-specific
markers (Supplementary Fig. S1d).
Next, we aimed to elucidate whether NF-κB and AP-1 were
responsible for these transcriptional changes. The hearts of SIRT3
knockout mice displayed increased phosphorylation of the NF-κB
inhibitor IκBα and, in accordance with this, p65 was increased in
the nucleus (Fig. 2b). To further corroborate this, we performed an
EMSA. NF-κB formed three major DNA-binding complexes, but
only complex III was slightly increased in the cardiac cells of SIRT3
knockout mice (Fig. 2c). In contrast, the formation of complexes I
and II was slightly reduced or not modified at all.
With regard to AP-1, FOS levels but not JUN, the other
partner of the AP-1 heterodimer, were increased in SIRT3
knockout mice (Fig. 2d, e). Consistent with this, AP-1
transcriptional activity was increased after SIRT3 deletion (Fig.
2f), and this was correlated with the enhanced expression of
the AP-1 target gene ATF4 (activating transcription factor 4;
Supplementary Fig. S1e), a profibrotic transcription factor that
controls the synthesis of type I collagen and other fibrosis-
related proteins.19 In fact, SIRT3 knockout mice spontaneously
developed myocardial fibrosis, since the collagen content in
the heart was higher in knockout mice than in WT mice (Fig.
2g). Assessment of cardiac geometric parameters showed a
clear tendency for smaller cavities in the presence of
nonhypertrophic walls in SIRT3 knockout mice (see LV EDD
and LV ESD in Fig. 2h and Supplementary Table S1). There was
also a nonsignificant decrease in some radial and longitudinal
parameters, such as EF, FS, MAPSE, and IRT. No differences in
heart rate were observed due to loss of SIRT3, as previously
reported.20
SIRT3 modulates TNF-α-induced inflammation and FOS/AP-1
activity in human cardiac cells
To further confirm the function of SIRT3 in the heart, we utilized
cultured cardiac cells of human origin (AC16), which were
transfected with a plasmid coding for SIRT3 (Supplementary Fig.
S2a–c). In the absence of a proinflammatory stimulus, SIRT3
overexpression significantly downregulated the mRNA expression
of MCP1 and SOCS3 (Fig. 3a). Interestingly, the predicted anti-
Fig. 1 SIRT3 deletion in knockout mice does not induce cardiac hypertrophy. Body weight a and heart weight to tibia length (HW/TL) ratio b
in SIRT3 knockout (KO SIRT3) mice and their wild-type (WT) littermates. c Representative hematoxylin and eosin stained micrographs showing
transverse sections from the left ventricle myocardium and quantification of cardiomyocyte cross-sectional areas. d Relative quantification of
Nppb (type B natriuretic peptide) and β-myosin heavy chain (β-MHC) mRNA expression. Graphs represent the quantification of adenine
phosphoribosyl transferase (Aprt)-normalized mRNA levels expressed as a percentage of the WT samples. The data are the mean ± SD
(Mann–Whitney test)
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inflammatory effect of SIRT3 was even more pronounced when a
proinflammatory stimulus was added to the cells, since it partially
but significantly prevented the increase in IL6 and MCP1
expression induced by TNF-α. Similar results were obtained with
SIRT3-overexpressing cells coincubated with palmitate (Supple-
mentary Fig. S3), a saturated free fatty acid that is responsible for
the activation of inflammation in the heart.21 As previously
reported,22 TNF-α stimulated the phosphorylation-induced
Fig. 2 SIRT3 knockout mice display inflammation in the heart. a Relative quantification of Icam1, Il6, Mcp1, Socs3, and Sod2mRNA expression in
SIRT3 knockout (KO SIRT3) and wild-type (WT) mice. bWestern blot analysis showing the levels of p-IκBαSer32/IκBα in total protein extracts and
p65 in nuclear protein fractions (NE) obtained from the same samples. The data are the mean ± SD. c EMSA data showing NF-κB DNA-binding
activity in the heart. Ab antibody; IC immunocomplex; NE nuclear extract. Western blot analysis showing the levels of FOS and JUN in cytosolic
d and nuclear e protein fractions obtained from heart samples of KO SIRT3 and WT mice. The graphs represent the quantification of adenine
phosphoribosyl transferase (Aprt)–normalized mRNA levels a or the normalized quantification of protein levels b, d, and e expressed as a
percentage of the control samples ± SD. f EMSA data showing AP-1 DNA-binding activity in the heart. g Representative images of Mason’s
trichrome staining and quantification of fibrosis expressed as a percentage of WT samples ± SD in the heart. h Representative M-mode
transthoracic echocardiographic images and graphs representing evaluations of EF, FS, LV EDD, and LV ESD diameters, and IVRT. The Data are
presented as the median ± interquartile range and were compared using the Mann–Whitney test. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. WT
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proteasomal degradation of IκBα and subsequent p65/NF-κB
nuclear translocation and activation (Fig. 3b). However, SIRT3
overexpression did not prevent or reduce the effects of TNF-α on
these proteins or on the transcriptional activity of NF-κB (Fig. 3b,
c). Regarding AP-1, TNF-α increased the protein levels of FOS (Fig.
3b) but not JUN (Supplementary Fig. S4); this increase was
prevented by SIRT3 overexpression. Assessment of the transcrip-
tional activity of AP-1 by EMSA demonstrated that SIRT3
Fig. 3 SIRT3 overexpression attenuates inflammation in human cardiac cells. a Relative quantification of IL6, MCP1, and SOCS3 mRNA
expression in human AC16 cardiac cells transfected with LacZ-carrying or SIRT3-carrying plasmids in the presence or absence of TNF-α (TNF,
10 ng/mL, 24 h). The graphs represent the quantification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-normalized mRNA
levels, expressed as a percentage of the control samples ± SD. b Western blot analysis showing the levels of IκBα in total protein extracts, p65
in nuclear protein fractions, and FOS in cytosolic (CP) and nuclear (NE) protein fractions obtained from the same samples. The graphs
represent the quantification of protein levels normalized to actin (total protein) or lamin B (nuclear protein), expressed as a percentage of the
control samples ± SD. c EMSA data showing NF-κB DNA-binding activity. Ab antibody; IC immunocomplex; NE nuclear extract. d EMSA data
showing AP-1 DNA-binding activity in the same samples depicted in panel a. e Relative quantification of ATF4, EDN-1, and TGFB1 mRNA
expression expressed as a percentage of the control samples ± SD. The data were compared by ANOVA followed by Tukey’s post hoc test. *P <
0.05, **P < 0.01, and ***P < 0.001 vs. LacZ; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LacZ+ TNF-α. f Pearson correlation coefficient between
SIRT3 and FOS gene expression in left ventricular myocardial tissue obtained from patients undergoing aortic valve replacement surgery. The
relative transcript levels of the target genes, in arbitrary units, were used to calculate the Pearson correlation coefficient
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overexpression downregulated its DNA-binding activity (Fig. 3d),
and accordingly, the mRNA expression of ATF4, EDN-1 (endothelin
1), and TGFB1 (TGF-β) was attenuated (Fig. 3e).
We next explored this phenomenon in left ventricular intrao-
perative biopsies of patients with severe aortic valve stenosis who
underwent aortic valve replacement surgery. Of note, the relative
expression of SIRT3 negatively correlated with that of FOS (Fig. 3f,
Pearson correlation coefficient r=−0.50), a finding that matched
our previous in vitro results.
SIRT3 also modulates inflammation and FOS levels in neonatal rat
cardiomyocytes
Transduction of neonatal rat cardiomyocytes with a recombinant
adenovirus expressing murine SIRT3 cDNA (AdSIRT3) yielded a
substantial increase in gene expression and protein accumulation
(Supplementary Fig. S5a, b). SIRT3 overexpression significantly
downregulated the mRNA expression of Icam1, Il6, and TNF-α,
particularly in TNF-α-treated cells (Fig. 4a). This anti-inflammatory
effect of SIRT3 correlated with an attenuation of Fos mRNA and
protein levels (Fig. 4b, c) and the downregulation of the
expression of the AP-1 target genes Atf4, Edn-1, and Tgfb1 (Fig.
4d). No statistically significant changes were found in p65 protein
levels in these cells (Supplementary Fig. S5b).
SIRT3 attenuates FOS/AP-1 signaling via histone H3 deacetylation
in chromatin
We next investigated the potential mechanisms by which SIRT3
regulates FOS levels. First, we examined overall acetylation levels
in total and nuclear protein extracts, and no statistically significant
changes were observed despite the increase in SIRT3 levels
(Supplementary Fig. S2d). The involvement of the deacetylase
activity of SIRT3 in its anti-inflammatory effect was demonstrated
by transfecting cells with a plasmid coding for a deacetylase
inactive mutant of SIRT3 (SIRT3H248Y), which did not abrogate the
TNF-α-induced expression of IL6 and MCP1 in AC16 cells (Fig. 5a).
Since SIRT3 overexpression correlated with a decline in FOS
gene expression (Fig. 5b), we focused on transcriptional mechan-
isms. The FOS gene promoter contains diverse regulatory
elements.23 A major element is the v-sis-inducible element (SIE),
which binds the phosphorylated STAT3 (signal transducer and
activator of transcription 3) transcription factor upon cytokine
treatment to participate in FOS promoter activation. Another key
element is the serum response element (SRE); when the protein
complex assembled on the SRE is phosphorylated by ERK1/2 or
p38 MAPK, FOS transcription is induced. Western blot analysis
revealed that neither STAT3 nor ERK1/2 were responsible for the
effects of SIRT3 on FOS expression levels (Fig. 5c, d). In contrast,
Fig. 4 SIRT3 modulates inflammation and FOS levels in neonatal rat cardiomyocytes. Relative quantification of Icam1, Il6, Tnf-α a, Fos b, Atf4,
Edn-1, and Tgfb1 d mRNA expression in neonatal rat cardiomyocytes overexpressing Sirt3 (AdSIRT3) or GFP control vector (AdGFP; 30 IFU per
cell, for 48 h) in the presence or absence of TNF-α (TNF, 10 ng/mL, 24 h). The graphs represent the quantification of the Gapdh–normalized
mRNA levels expressed as a percentage of the control samples ± SD. c Western blot analysis showing FOS protein levels in total protein
extracts obtained from the same samples depicted in panel a. The graph represents the quantification of protein levels normalized to GAPDH
expressed as a percentage of the control samples ± SD. The data were compared by ANOVA followed by Tukey’s post hoc test. *P < 0.05, **P <
0.01, and ***P < 0.001 vs. AdGFP; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. AdGFP+ TNF-α
SIRT3-mediated inhibition of FOS through histone H3 deacetylation. . .
Palomer et al.
5
Signal Transduction and Targeted Therapy            (2020) 5:14 
p38 MAPK activity was evidently diminished by SIRT3 (Fig. 5e).
However, treatment with the p38 MAPK inhibitor SB202190 did
not reduce the expression of the FOS gene, but rather had the
opposite effect, thus ruling out the transcriptional control of the
latter by this kinase (Fig. 5f). The FOS promoter also contains an
AP-1 consensus binding site that may positively regulate its
transcription.24 Specific pharmacological inhibition of AP-1 activity
by SR-11302 significantly downregulated the transcription of FOS
and the AP-1-target genes ATF4 and EDN-1 (Fig. 5g), suggesting
that the SIRT3-mediated effects were due, at least in part, to the
attenuation of AP-1 activity.
On the other hand, previous reports indicate that nuclear
sirtuins (SIRT1, SIRT2, and SIRT6) deacetylate H3 and H4 histones in
chromatin in a gene-specific manner.11,25,26 In the framework of
gene expression, histone H3 acetylation at specific lysine residues
(H3K56, H3K14, H3K9, and H3K27) is associated with actively
transcribed genes, while deacetylation correlates with repression.
For this reason, we examined the potential role of this epigenetic
mechanism. As shown in Fig. 6a, forced SIRT3 expression reduced
overall histone H3 acetylation, whereas its knockdown with
small interfering RNA (siRNA) yielded an increase in H3 acetylation
(Fig. 6b). Histone H4 acetylation was not affected under any of
Fig. 5 FOS is not transcriptionally regulated by STAT3 or MAPK. a Relative quantification of IL6 and MCP1 mRNA expression in human AC16
cardiac cells transfected with LacZ-carrying, SIRT3-carrying, or SIRT3H248Y-carrying plasmids in the presence or absence of TNF-α. b Relative
quantification of FOS mRNA expression in human AC16 cardiac cells transfected with LacZ-carrying or SIRT3-carrying plasmids in the presence
or absence of TNF-α. Western blot analysis showing the protein levels of phosphorylated ERK1/2Thr202/Tyr204/ERK1/2 c, phosphorylated
STAT3Ser727/STAT3 d, and phosphorylated p38Thr180/Tyr182/p38 MAPK e in total protein extracts obtained from human AC16 cardiac cells
transfected with LacZ-carrying or SIRT3-carrying plasmids in the presence or absence of TNF-α (TNF, 10 ng/mL, 24 h). f Relative quantification
of FOS mRNA levels in human AC16 cardiac cells incubated in the presence or absence of the p38 MAPK inhibitor SB202190 (10 μmol/mL,
24 h). The graphs represent the quantification of protein levels normalized to actin and are expressed as a percentage of the control samples
± SD. g Relative quantification of FOS, ATF4, and EDN-1 mRNA levels in human AC16 cardiac cells incubated in the presence or absence of
the AP-1 inhibitor SR-11302 (10 μmol/L, 24 h). The graphs represent the quantification of the GAPDH-normalized mRNA levels a, b, f, and g or
the quantification of protein levels normalized to GAPDH c–e, expressed as a percentage of the control samples ± SD. Comparisons were
performed by ANOVA followed by Tukey’s posttest (panels a–e) or unpaired two-tailed Student’s t-test (panels f and g). a–e *P < 0.05, **P <
0.01, and ***P < 0.001 vs. LacZ; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LacZ+ TNF-α; ┼P < 0.05, ┼┼P < 0.01, and ┼┼┼P < 0.001 vs. SIRT3; &P <
0.05, &&P < 0.01, and &&&P < 0.001 vs. SIRT3+ TNF-α. f and g *P < 0.05, **P < 0.01, and ***P < 0.001 vs. Control
SIRT3-mediated inhibition of FOS through histone H3 deacetylation. . .
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these conditions (Supplementary Fig. S6). A chromatin immuno-
precipitation (ChIP) assay was performed to examine whether
SIRT3 is required for H3 deacetylation at the promoter of the FOS
gene. This technique demonstrated that the anti-H3K27 acety-
lated (H3K27ac) antibody but not the mock control effectively
coimmunoprecipitated H3K27ac and the FOS promoter under
basal conditions. Importantly, ChIP assays revealed that H3K27
acetylation at the FOS promoter was significantly reduced
following SIRT3 overexpression (Fig. 6c), which was consistent
with its transcriptional repression. In contrast, in cells depleted of
SIRT3 (Fig. 6d) by means of siRNA-mediated gene silencing, H3K27
was hyperacetylated at this promoter.
DISCUSSION
Metabolic disorders including obesity and type 2 diabetes may
induce structural and functional alterations in the heart muscle
that lead to compromised myocardial function, cardiac hyper-
trophy and, ultimately, heart failure, which is the foremost cause
of death in these patients.27 Several, but not all, studies have
reported that mice with reduced SIRT3 expression develop cardiac
hypertrophy, interstitial fibrosis, and contractile dysfunc-
tion.15,16,20,28–30 The results presented herein reveal that SIRT3
knockout mice exhibited cardiac fibrosis and inflammation,
although we did not observe cardiac hypertrophy or cardiac
dysfunction, as inferred from echocardiographic data, unlike what
was previously reported with the same mouse strain.15,30
However, our data conform to other previously published results
in which cardiac function was preserved in SIRT3 knockout mice
despite spontaneously developing massive cardiac fibrosis.31–33
We do not know the reason for the discrepancies regarding
cardiac morphology and function among these studies, although
the age of the mice might be an important issue.
In this study, we found that overexpression of SIRT3 but not its
inactive mutant (SIRT3H248Y) in cardiac cells of human origin and
in neonatal rat cardiomyocytes exerted an anti-inflammatory
effect, which was even more evident in the presence of
proinflammatory stimuli. Further reinforcing these data, suppres-
sion of SIRT3 increased the transcription of inflammatory genes in
the hearts of knockout mice. Myocardial fibrosis was also elevated
in cardiac tissue of SIRT3 knockout mice, as reported in other
studies,28,31 and consistent with this, the expression of TGF-β,
ATF4, and EDN-1 was inhibited by SIRT3 overexpression in AC16
cells and in neonatal rat cardiomyocytes. This effect of SIRT3 was
mostly mediated by its inhibitory effect on the FOS subunit of AP-
1. In the heart, AP-1 decreases contractility and induces
cardiomyocyte hypertrophy, inflammation, and fibrosis, which
eventually result in heart failure.4 In fact, it is widely known that
the FOS/AP-1 pathway induces the formation of endothelin-1,
fibronectin, and TGF-β and the deposition of collagen, favoring
the emergence of cardiac fibrosis.4,7,9 Overall, our results support
the idea that AP-1 plays a crucial role in controlling inflammation
and fibrosis in the heart and are consistent with the aforemen-
tioned data indicating that, in addition to NF-κB, AP-1 and other
transcription factors also control cardiac cytokine and chemokine
mRNA expression.21
An intriguing issue regarding the results reported herein is that
the effects of SIRT3 spread to the nucleus, since there is still some
controversy surrounding its intracellular localization. Until recently,
SIRT3 activity had been regarded as being exclusively localized in
the mitochondria, but there is now evidence that it is also found in
the cytoplasm and the nucleus.15,34–36 Indeed, nuclear substrates
of SIRT3 activity have already been recognized, including the H3
and H4 histones and the transcription factor FOXO3a.15,17,37 Now,
we report for the first time that SIRT3 modulates another nuclear
transcription factor, FOS/AP-1. In particular, we observed changes
in FOS levels in both the nucleus and the cytoplasm; hence, SIRT3
might perform genomic (i.e., inflammation) and nongenomic38
actions through its effect on FOS protein levels. As previously
reported in palmitate-treated pancreatic cells,39 nuclear and
cytoplasmic SIRT3 protected cardiac cells from TNF-α-induced
inflammation, despite being less abundant than mitochondrial
Fig. 6 SIRT3 attenuates FOS/AP-1 signaling via H3K27 deacetylation at the chromatin. Western blot analysis showing the protein levels of
acetylated histone H3 in nuclear protein extracts obtained from human AC16 cardiac cells transfected with a LacZ-carrying or SIRT3-carrying
plasmids or b scrambled siRNA (siRNA control) or SIRT3 siRNA. The graphs represent the quantification of protein levels normalized to lamin B
expressed as a percentage of the control samples ± SD. ChIP assay for the determination of H3K27 acetylation levels at the FOS promoter in
human AC16 cardiac cells transfected with LacZ or SIRT3-carrying plasmid c, scrambled siRNA (siRNA control) or SIRT3 siRNA d. The data are
the mean ± SD, and comparisons were performed by unpaired two-tailed Student’s t-test. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. LacZ a and
c or siRNA control b and d
SIRT3-mediated inhibition of FOS through histone H3 deacetylation. . .
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SIRT3. Bearing in mind that other sirtuins (i.e., SIRT1, 6, and 7) are
more abundant in the nucleus, and it is feasible that SIRT3 only acts
on a small and selective subset of proteins and even histone
residues,34 thus accounting for the lack of changes in the overall
acetylation pattern in our study. Another possibility is that SIRT3 has
a crucial function in the nucleus but is quickly and negatively
regulated through its physical nuclear exclusion.34 Last but not
least, we demonstrate that SIRT3 is located in the nucleus of cardiac
cells and is recruited to the FOS promoter to deacetylate H3K27,
thus hindering the accessibility of chromatin to DNA-binding
factors and repressing transcription in a gene-specific manner.
Our findings show that SIRT3, by means of its action on FOS/AP-
1, plays a key role in modulating fibrosis and the inflammatory
response in cardiomyocytes. This is important because FOS
expression is known to be increased during cardiac hypertrophy
and heart failure. Since fibrosis and inflammation are crucial
during the development of these cardiomyopathies, our data
suggest that SIRT3 may be useful for treating these conditions.
SIRT3 is also involved in the pathophysiology of obesity and type 2
diabetes.39,40 Interestingly, FOS transcription is increased as a
result of insulin shortage in the heart4 and in adipose tissue of
diabetic rats,41 while a frequently recognized polymorphism that
decreases SIRT3 activity is linked with metabolic syndrome.42
Likewise, metformin, in addition to promoting glucose uptake,
displays anti-inflammatory effects that are explained, at least in
part, by the stimulation of SIRT3.40 Metabolic diseases contribute
to the progression of cardiac hypertrophy and heart failure,
thereby adding pharmacological value to SIRT3 and highlighting a
new alternative approach for targeting insulin resistance-related
diseases. In conclusion, our findings have considerable conse-
quences not only for the treatment and management of heart




[γ-32P]-ATP was purchased from PerkinElmer (Waltham, MA, USA),
bovine serum albumin (BSA) was purchased from Calbiochem
(Darmstadt, Germany), and SR-11302 was purchased from Tocris
Bioscience (Bristol, United Kingdom). All other reagents were
purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
Antibodies against acetylated-lysine (#9441), total (#9102), and
phosphorylated (Thr202-Tyr204, #9101) ERK1/2 MAPK, phosphory-
lated IκBα (Ser32, #2859), total (#9212) and phosphorylated
(Thr180-Tyr182, #9211) p38 MAPK, SIRT3 (#5490) and phosphory-
lated (Ser727, #9134) STAT3 were obtained from Cell Signaling
Technology (Danvers, MA, USA). Antibodies against FOS (sc-253),
total IκBα (sc-371), JUN (sc-44), Lamin B (sc-6216), OCT1 (sc-232),
p65 (sc-109), and total STAT3 (sc-482) were purchased from Santa
Cruz Biotechnology, Inc. (Heidelberg, Germany), acetylated
histone 4 (H4) was purchased from R&D Systems (AF5215,
Minneapolis, MN, USA), the actin antibody was purchased from
Sigma-Aldrich Co. LLC. (A5441), and acetylated-histone 3 (H3, #06-
599) and GAPDH antibodies were from Millipore (MAB374, Saint
Charles, MO, USA).
Cell culture and transfection
The human AC16 cell line was grown and treated as previously
described.21,43 For overexpression analyses, AC16 cells were
transfected for 48 h with Lipofectamine 2000 according to the
manufacturer’s instructions (Life Technologies, Barcelona, Spain)
with the pcDNA4-myc-HisA-SIRT3 plasmid (Addgene #24924),
which corresponded to the human full-length SIRT3 gene, the
pcDNA4-myc-HisA-H248Y-SIRT3 plasmid (Addgene #24917), which
coded for a deacetylase-inactive SIRT3 mutant,14 and the
corresponding LacZ-carrying plasmid as a control. SiRNA-
mediated SIRT3 gene silencing was performed by transfecting
AC16 cells with human SIRT3 siRNA (Santa Cruz Biotechnology,
Inc.), using scrambled siRNA as a control.
Neonatal rat cardiomyocytes were isolated and cultured as
described by Palomer et al. 44 Neonatal rat cardiomyocytes were
transduced with a recombinant adenovirus expressing murine
Sirt3 cDNA (AdSirt3) or an AdCMV-GFP control vector (AdGFP) at
30 infectious units (IFU)/cell for 48 h in serum-free medium.
Mouse cardiac sample preparation
Male SIRT3 knockout mice (B6; 129S5-SIRT3Gt(neo)218Lex) were
purchased from the Mutant Mouse Regional Resource Center.
Mice lacking SIRT3 (Supplementary Fig. S1a, b) were viable, fertile,
and displayed a normal life span. The mice were housed under
standard light–dark cycle (12-h light/dark cycle) and temperature
(21 ± 1 °C) conditions, and food and water were provided ad
libitum. Ventricular tissue was obtained from 7- to 9-month-old
male mice.
All animal experiments were approved by the Institutional
Animal Care and Use Bioethics Committee at the University of
Barcelona, as stated in Law 5/21 July 1995 passed by the Generalitat
de Catalunya, and conformed to the Guide for the Care and Use of
Laboratory Animals published by The National Academies Press (US
National Institutes of Health, 8th edition, 2011).
Transthoracic echocardiography of mice
The mice were anesthetized using a combination of isoflurane (5%)
and oxygen (2 L/min), which was subsequently reduced to 1.5%
isoflurane to maintain the heart rate in the range of 350–450 beats/
min. Transthoracic echocardiography was performed from a long-
itudinal parasternal plane using a Vivid Q (GE Healthcare, Norway)
echocardiograph. Off-line analysis of the acquired images was used
to determine ejection fraction (EF), shortening fraction (SF), septal
and left ventricular free wall thicknesses, mitral annular plane
systolic excursion (MAPSE), and end diastolic and end systolic
diameters by M-mode. Isovolumetric relaxation time (IRT) and early
transvalvular filling (E) and early diastolic annular peak (E′) velocities
were measured via pulsed wave conventional and tissue Doppler,
respectively.
Histology
Hearts were fixed in 4% buffered paraformaldehyde and paraffin-
embedded for subsequent hematoxylin and eosin or Masson’s
trichrome staining. Transverse myocardial sections (5 μm thick)
were visualized using an Olympus BX41 microscope (Olympus
Iberia, Barcelona, Spain), and digital images were obtained at ×200
magnification. The cardiomyocyte cross-sectional area was ana-
lyzed in two randomly chosen sections per mouse using ImageJ
software (National Institutes of Health, USA). The degree of fibrosis
was determined in two randomly chosen frames from Masson’s
trichrome-stained sections using ImageJ software. The percentage
of interstitial fibrotic areas was calculated as the fraction of the
light-blue-stained area × 100%.
RNA preparation and analysis
RNA was isolated with Ultraspec reagent and subsequently
cleaned (NucleoSpin RNA; Macherey-Nagel, Düren, Germany).
Relative levels of specific mRNAs were quantified by real-time
RT-PCR as previously described.45 The sequences of the primers
used for amplification are shown in Supplementary Table S2.
Immunoblot analysis and coimmunoprecipitation studies
Isolation of total protein extracts and cytosolic and nuclear protein
fractions from AC16 cardiac cells or frozen tissue slides was
performed as previously described.45 For immunoblotting, protein
fractions were resolved by 10% SDS–PAGE and transferred to
polyvinylidene difluoride membranes. Proteins were identified by
using several antibodies and a chemiluminescence kit (PerkinEl-
mer, Waltham, MA, USA).
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For coimmunoprecipitation studies, FOS antibody was first
bound to Protein A/G Plus agarose beads by covalent crosslinking
with dimethyl pimelimidate and following a standard method.
Next, cell nuclear extracts (20 μg) were diluted with dilution buffer
(10 mmol/L PBS, 50 mmol/L KCl, 0.05 mmol/L EDTA, 2.5 mmol/L
MgCl2, 8.5% glycerol, 1 mmol/L dithiothreitol, 0.1% Triton X-100,
BSA 2%, and 1mg/mL nonfat milk) and incubated on a rocker
platform for 18 h at 4 °C with 100 μL Protein A/G Plus agarose
beads containing 2 μg of bound FOS antibody. The agarose beads
were centrifuged and washed with PBS. After centrifugation, the
protein was eluted, and the supernatant was subjected to
electrophoresis and immunoblotting with the anti-acetylated-
lysine antibody.
Electrophoretic mobility shift assay (EMSA)
EMSAs were carried out using double-stranded oligonucleotides
for the consensus binding sites of AP-1 and NF-κB (Santa Cruz
Biotechnology) as previously reported.45
Chromatin immunoprecipitation
Approximately three million AC16 cells were transfected, as
described above, with SIRT3-carrying or LacZ-carrying plasmids
and SIRT3 siRNA or scrambled siRNA and fixed in 1%
paraformaldehyde. Two independent replicates of fixed cells
per treatment were pooled and sonicated to an average length
of 200–1000 bp using a Bioruptor sonicator (Diagenode, Liège,
Belgium). Sonication profiles were verified by using a TapeSta-
tion instrument (Agilent Genomics, Santa Clara, CA, USA).
Chromatin was precleared with preblocked Dynabeads Protein
G (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at 4 °C and
immunoprecipitated with anti-H3K27ac (Abcam, ab4729) or anti-
rabbit IgG (mock samples; Cell Signaling, #2729) overnight at 4 °
C. Immune complexes were retrieved using preblocked Dyna-
beads Protein G (Thermo Fisher Scientific) for 2 h at 4 °C. The
beads were subsequently washed and eluted prior to DNA
purification using phenol:chloroform extraction. ChIP and input
DNA were quantified.
Real-time quantitative PCR was used to assess specific enrich-
ment at positive and negative genomic sequences where the
protein of interest is known to be bound. The enrichment of target
genes was calculated using amylase (Amy2A prom) and nanog
(Nanog TSS) promoters as negative controls, as well as IgG as a
control for nonspecific genomic DNA binding. Commercial
SimpleChIP Human AFM Intron 1 Primers (Cell Signaling) were
also used as negative control primers. Real-time q-PCR was
performed in triplicate for each IP reaction using the following
primer sets: Amy2A prom forward (Fwd) 5′-TGCTGCCAGAACC-
TAAGAAAA-3′; Amy2A prom reverse (Rev) 5′-TTGAGGG-
CAAACTGTTTATTCA-3′; Nanog TSS Fwd 5’-AAAGCTTGCCTTGCTTT
GAA-3’; Nanog TSS Rev 5’-AGTCTCCGTGTGAGGCATCT-3’; Fos prom
Fwd 5’-GAGCAGTTCCCGTCAATCC-3’; and Fos prom Rev 5’-
GCATTTCGCAGTTCCTGTCT-3’. ChIP-qPCR data were normalized
by using the fold enrichment method.
Human samples
This study was carried out using left ventricular myocardial
intraoperative biopsies obtained from a cohort of 26 male patients
(Supplementary Table S3) who were diagnosed with isolated
severe aortic stenosis and underwent aortic valve replacement
surgery in the University Hospital Marqués de Valdecilla in
Santander (Spain). Subepicardial biopsies (40–80mg) were taken
from the left ventricular lateral wall with a Tru-cut needle during
the surgical procedure. Samples were all harvested by the same
surgeon in a protocolized manner and always from the same
location in themargo obtusus of the heart. Total RNA was obtained
by TRIzol (Invitrogen) extraction. Real-time RT-PCR was conducted
using specific TaqMan assays (Thermo Fisher) for the genes FOS
and SIRT3.
This study followed the Declaration of Helsinki guidelines for
biomedical research involving human subjects. Written informed
consent was obtained from all patients prior to inclusion in
the study.
Statistical analysis
Statistical differences were established by either the
Mann–Whitney test (in vivo experiments) and Student’s t-test
for comparisons within two groups or ANOVA followed by
Tukey’s test for multigroup comparisons using GraphPad Prism
software.
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